GMRE Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.77%, SMA50 2.37%, SMA200 5.62%). The stock’s 14-day RSI is 53.94 (neutral), while the ATR of 0.91 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -21.36% below its high and over 23.86% above its low.

Global Medical REIT Inc. generated EPS of -$0.25 over the past year. Five-year average earnings growth is -34.34%. The latest quarter delivered EPS of -$0.45. The next quarter is forecast at $0.07. Next year's EPS is expected at -$73.00. Analyst sentiment is neutral. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $41.00 to $40.00. The high target offers 14.72% upside. The low target suggests 11.92% downside. The mean target is $40.50. This offers 13.32% upside. Global Medical REIT Inc. earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by -142.86%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -122.73% in August 06, 2024.

Global Medical REIT Inc. (NYSE:GMRE) closed at $35.74 USD, losing -$0.45 (-1.24%) from the previous close of $36.19. The stock is currently mid-range between its 52-week high and low $29.05 and $45.75. With a market capitalization of about $478.13 million, Global Medical REIT Inc. is classified as a small-cap and shows market-like volatility (beta ~1.20). Key stats such as the average daily volume over the past year has been around 105.80 thousand shares, in line with its 52-week average. Headquartered in Bethesda, MD, Global Medical REIT Inc. operates in the Real Estate sector and the REIT - Healthcare Facilities industry. Led by CEO Mark O. Decker Jr., the company employs approximately 26 people and listed since June 30, 2016. Global Medical REIT Inc. is net-lease medical office REIT that acquires purpose-built specialized healthcare facilities and leases those facilities to strong healthcare systems and physician groups with leading market share.

Global Medical REIT Inc. last paid a dividend of 3.3 per share, this equals a trailing yield of roughly 8.44%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.01. This means the shares are trading below this model’s fair value.

Global Medical REIT Inc. has 66.88 million shares outstanding. The public float is 62.91 million shares, elevated short interest at 3.96% of float. This equals 2.49 million shares. The short ratio is 3.5 days. Institutional investors hold 72.59% of the float. Insiders own 5.91%. CHAN FAI holds 7.50 million shares, Huang Yanping has 3.72 million shares and Zhang Jing Guo has 3.72 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Global Medical REIT Inc. trades at a P/E ratio of -39.44, slightly below the S&P 500 average, with a price-to-sales ratio of 3.23 and a price-to-book ratio of 0.94 suggesting the stock is closer to book value. The P/FCF stands at -13.27, also below market averages.

Global Medical REIT Inc. (NYSE:GMRE) shares are flat 6.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Global Medical REIT Inc. trading at a premium to the broader market with a P/E of -39.44. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $15.83, suggesting -56.0% downside. Our AI forecast model points to short-term strength (2.72% over two weeks), a medium-term rise (8.67% over three months), and a longer-term loss (-21.82% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Global Medical REIT Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.72%, with price expected at $36.96 by March 06, 2026, within a range of $36.20 to $37.60 3-Month Outlook: Projected rise of 8.67%, reaching $39.10 by May 21, 2026, with a range of $36.78 to $41.54. 1-Year Outlook: Projected loss of -21.82%, with price at $28.13 by February 19, 2027, within a range of $26.83 to $29.52.